

Health Care Market Oversight

Transaction 073

Abbott – Exact Sciences

Preliminary Review Report

March 12, 2026



About this Report

This report summarizes analyses and findings from Oregon Health Authority’s preliminary review of the proposed material change transaction involving Abbott Laboratories and Exact Sciences. It accompanies the Findings of Fact, Conclusions of Law, and Final Order (“Preliminary Review Order”) issued by Oregon Health Authority on March 12, 2026. For legal requirements related to the proposed transaction, please reference the [Preliminary Review Order](#).

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-945-6161. We accept all relay calls.

If you have any questions about this report or would like to request more information, please contact hcmo.info@oha.oregon.gov.

About this Report.....	2
Executive Summary	3
Introduction.....	5
Proposed Transaction	6
Findings & Potential Impacts	11
Conclusions.....	14
Acronyms & Abbreviations	15
Appendix A: OHA’s Review	16
References	17

Executive Summary

The [Health Care Market Oversight](#) (HCMO) program reviews proposed health care business deals to make sure they support Oregon’s goals of health equity, lower costs, increased access, and better care. After completing a review, the Oregon Health Authority (OHA) issues a decision about whether a business deal, or transaction, involving a health care company can proceed.

Proposed Transaction

On February 10, 2026, OHA accepted a complete [Notice of Material Change Transaction](#) (“notice”) from Abbott Laboratories (“Abbott”). The notice describes plans for Abbott to acquire Exact Sciences Corporation (“Exact Sciences”). Abbott and Exact Sciences are referred to in this report as “the entities.” Abbott operates diagnostic, toxicology lab, and durable medical equipment businesses. Exact Sciences offers products that focus on cancer detection, including cancer screening, precision oncology and genetic testing. Both entities offer services in all 50 states, including Oregon. Post-transaction, Exact Sciences will become a wholly owned subsidiary of Abbott.

OHA’s Review

OHA completed a 30-day preliminary review of the proposed transaction. During the review, OHA assessed the likely impact of the transaction across various domains in alignment with preliminary review criteria.

Key Findings

The proposed transaction is unlikely to significantly impact access to services in Oregon.

Abbott and Exact Sciences provide different types of services in Oregon.

While both entities provide diagnostic services, the majority of Abbott’s business in Oregon is workplace drug and pre-employment screening, while Exact Sciences focuses on cancer screening.¹ As such, the transaction will not result in horizontal consolidation in the state.

The proposed transaction is unlikely to result in significant changes to services or market share in Oregon.

The entities state that Exact Sciences will continue to operate as a standalone business and the transaction will not affect the availability of services, stating that there will be no changes to geographic areas served and type and level of services offered.² Abbott and Exact Sciences are not direct competitors for their main business in Oregon and the transaction will not result in horizontal consolidation.³

Conclusions and Decision

Based on preliminary review findings, **OHA approved the transaction on March 12, 2026** (See [Preliminary Review Order](#)). OHA approved the proposed transaction based on the following criterion:

- 1. The transaction is not likely to substantially alter the delivery of health care in Oregon.**

Following the transaction, no substantial changes are expected to existing services or products available in Oregon. Exact Sciences is expected to continue to operate as a standalone business. Abbott and Exact Sciences are not direct competitors for their operations in Oregon, and the transaction will not result in horizontal consolidation in the state.

As required by statute, OHA will conduct follow-up analyses one, two, and five years after the transaction is complete. OHA's monitoring will assess whether the entity keeps the commitments included in the notice. More broadly, OHA will monitor changes that occur after the close of the transaction.

Introduction

OHA's Health Care Market Oversight program (HCMO), launched in March 2022, reviews proposed health care transactions such as mergers, acquisitions, and affiliations to ensure they support statewide goals related to cost, equity, access, and quality. The HCMO program is governed by [Oregon Revised Statute 415.500 et seq.](#) and [Oregon Administrative Rules 409-070-0000 through -0085.](#)

In the authorizing statute, the Oregon Legislature specified what types of proposed transactions are subject to review and the criteria OHA must use when analyzing a given proposed transaction. The Oregon Legislature also authorized OHA to decide the outcome of a proposed transaction. After reviewing a given proposed transaction, OHA may approve, approve with conditions, or disapprove the transaction.

The HCMO program fits within OHA's broader mission of ensuring all people and communities can achieve optimum physical, mental, and social well-being through partnerships, prevention, and access to quality, affordable health care. The program also supports OHA's goal of eliminating health inequities by 2030.

The Preliminary Review Process

Health care entities planning a transaction that is subject to HCMO review must submit a Notice of Material Change Transaction ("notice") to OHA. The notice must comply with the requirements of OAR 409-070-0045 and be submitted to OHA no later than 180 days before the planned closing date of the transaction. OHA is required to complete a preliminary review of the proposed transaction, in accordance with OAR 409-070-0055, within 30 calendar days of confirming receipt of a complete notice, unless the review period is tolled or extended in accordance with OAR 409-070-0085.

For OHA to approve a transaction following preliminary review, OHA must determine that the transaction meets at least one of the following criteria specified in OAR 409-070-0055(2):

- a) The material change transaction is in the interest of consumers and is urgently necessary to maintain the solvency of an entity involved in the transaction;
- b) The material change transaction is unlikely to substantially reduce access to affordable health care in Oregon;
- c) The material change transaction is likely to meet the criteria set forth in OAR 409-070-0060;
- d) The material change transaction is not likely to substantially alter the delivery of health care in Oregon; or
- e) Comprehensive review of the material change transaction is not warranted given the size and effects of the transaction.

If OHA is unable to determine that the proposed transaction meets at least one of the above criteria, OHA must conduct a comprehensive review pursuant to ORS 415.501(7)(a) and OAR 409-070-0055(3).

Transaction Notice Submission

On February 10, 2026, OHA accepted a complete Notice of Material Change Transaction (“notice”) from Abbott Laboratories (“Abbott”) with respect to its proposed acquisition of Exact Sciences Corporation (“Exact Sciences”).

OHA reviewed the notice and determined, based on the facts in the notice, that the transaction is subject to review. The entities party to the transaction meet the revenue thresholds specified in [OAR 409-070-0015\(1\)](#) and the proposed transaction is otherwise covered by the program in accordance with [OAR 409-070-0010](#).

After receipt of the complete notice, OHA began a preliminary review of the proposed transaction. This report describes the transaction and summarizes OHA’s findings and conclusions from the preliminary review.

Public Input

OHA solicited public comments on the proposed transaction during the preliminary review. On February 10, 2026, OHA posted a comment form to the [Transaction Notices and Reviews](#) page of the HCMO website and emailed subscribers to HCMO program updates to inform them about the opportunity to provide comment. OHA accepted comments via the form, phone, and by email to hcmo.info@oha.oregon.gov. OHA received 0 public comments.

Proposed Transaction

Through this proposed transaction, Abbott plans to acquire Exact Sciences.⁴ Abbott and Exact Sciences both operate diagnostic services in all 50 states, including Oregon.⁵

Entities Involved

Abbott

Abbott Laboratories is a publicly-traded, for-profit company incorporated in 1900 and incorporated in Illinois.⁶⁷ Abbott offers many health care products and services, including the following business:⁸




- Diagnostic testing: products and solutions for health care and at-home settings, including tests for influenza, HIV, COVID, hepatitis, and other infectious diseases;⁹
- Toxicology lab: alcohol and drug screening services ;¹⁰
- Pharmaceuticals: branded and generic products marketed and sold outside the United States in “emerging markets”;¹¹
- Nutritional products: pediatric and adult nutritional products, such as infant formula, oral electrolyte solutions like Pedialyte, meal replacement drinks like Ensure, and more; and¹²
- Medical devices and durable medical equipment (DME): products designed to manage cardiovascular diseases, diabetes chronic pain, and movement disorders¹³.

Abbott Laboratories provides services in all 50 states, including Oregon, and worldwide.¹⁴¹⁵ Globally, Abbott has approximately 115,000 employees.¹⁶ In the United States, Abbott has two health care businesses that provide health care services: a toxicology lab business and Acelis Connected Health, a DME, software, and remote patient monitoring services provider.¹⁷ Abbott’s toxicology lab business has approximately 815 employees nationwide and Abbott’s Acelis business has approximately 235 employees nationwide. Neither business has full-time employees in Oregon.¹⁸

Organizational Structure and Governance

Abbott is governed by a board of directors currently consisting of 11 independent directors and Abbott Chief Executive Officer (CEO) Robert B. Ford, who serves as Chairman of the Board.¹⁹ Abbott’s Executive Team consists of CEO Robert B. Ford and 19 Executive Vice Presidents or Senior Vice Presidents.²⁰

A simplified organizational chart is included below, see [Abbott Organizational Charts](#) for the complete Abbott organizational chart with all subsidiaries.



Toxicology Lab Business

Abbott owns and operates four dedicated toxicology clinical labs – located in California, Louisiana, and Virginia – and provides services in all 50 states.²¹ Abbott’s U.S. toxicology lab business has the following three major segments:

Business Segment	Description
U.S. Workplace Solutions	Abbott provides workplace screening and eligibility services including drug and alcohol testing and pre-employment physical and occupational health services. ²²
U.S. Government	Abbott provides lab services, rapid tests, and drug testing programs to U.S. federal, state, and local government agencies. ²³
U.S. Reagents	Abbott manufactures reagents to screen for relevant substances, including urine and oral fluid sample types for clinical labs, reference labs, treatment centers, forensic labs, and segments of the judicial system. ²⁴

Acelis Connected Health

Acelis Connected Health provides remote patient monitoring services, specializing in managing chronic conditions.²⁵ Abbott's Acelis business includes the following segments:

Business Segment	Description
INR testing services	Acelis provides remote patient monitoring PT-INR (prothrombin time - international normalized ratio) anticoagulation services for patients on anticoagulation medicines. ²⁶
VAD	Acelis provides external Vascular Assisted Device (VAD) equipment and supplies for outpatient support and remote patient monitoring. ²⁷
Additional related digital offerings	Acelis offers software licensed to health care providers that allow providers to remotely monitor patients. Acelis also offers an app that allows patients and providers to access information and software features. ²⁸

Exact Sciences

Exact Sciences is a publicly-traded, for-profit diagnostic company headquartered in Wisconsin.²⁹ Established in 1995, Exact Sciences offers products and technology that focus on cancer detection, with service offerings include cancer screening, precision oncology and genetic testing.³⁰ Exact Sciences provides these products and services both internationally and in all 50 states, including Oregon.³¹



Exact Sciences has approximately 6,700 employees, 30 of which are based in Oregon.³² Exact Sciences owns and operates six clinical laboratories – located in California, Maryland, New York, Pennsylvania, and Rhode Island.³³

Exact Sciences offers products for early detection of cancers, treatment guidance, monitoring cancer reoccurrence, therapy selection, including the following:


Product	Description
Cologuard® and Cologuard Plus™	Non-invasive stool test that screens for colorectal cancer in adults 45+ at average risk.
Oncoguard® Liver	Blood test that helps find the most common liver cancer in people liver disease or who are at higher risk for it.
Riskguard™	Blood or saliva test that can uncover hereditary risk for certain cancer and help inform monitoring and treatment plans.
Cancerguard™	Blood test designed to help find multiple cancers in earlier stages.
Oncotype DX® Breast DCIS Score	Tumor-tissue ductal carcinoma in situ breast cancer test that indicates the probability of recurrence and benefit from radiation therapy.

Product	Description
Oncotype DX® Breast Recurrence Score	Tumor-tissue early stage breast cancer test that estimates the risk of distant recurrence and benefit from chemotherapy.
Oncotype DX® Colon Recurrence Score	Tumor-tissue colon cancer test that quantifies the risk of recurrence and guides treatment.
Oncodetect™	Tumor-informed molecular residual disease test that can detect circulating tumor DNA in the blood during or after cancer treatment.
OncoExTra™	Tumor-tissue test that provides therapy selection guidance for advanced solid tumor cancers.

Additionally, Exact Sciences operates Prevention Genetics, a subsidiary which offers a variety of comprehensive genetic tests related to various conditions and rare diseases.³⁴

Organizational Structure and Governance

Exact Sciences is governed by a Board of Directors consisting of Chairman and CEO Kevin T. Conroy, former Chief Legal Officer Scott Coward, and seven independent directors.³⁵ A simplified organizational chart is included below, see [Exact Sciences Organizational Chart](#) for the complete organizational chart with all subsidiaries.



Rationale for the Transaction

Through the proposed transaction, Abbott seeks to enter the cancer diagnostics market.³⁶ The entities state that they expect the transaction will allow Abbott to serve “millions more people.”³⁷ Prior to the transaction, Abbott has a larger global presence than Exact Sciences, which the entities state will create growth opportunities for Exact Sciences.³⁸


Transaction Terms

On November 19, 2025, Abbott entered into an agreement to acquire Exact Sciences. At the close of the proposed transaction, Abbott will pay \$105 per common share in cash, representing a total value of roughly \$21 billion.³⁹ Abbott also expects to absorb roughly \$1.8 billion of Exact Sciences' debt.⁴⁰ Abbott plans to fund the purchase of Exact Sciences with cash on hand and financing, and has secured a loan of up to \$20 billion.⁴¹

To effectuate the transaction, Exact Sciences will merge with Badger Merger Sub I, Inc., a wholly owned subsidiary of Abbott. Exact Sciences will survive the merger to become a wholly owned subsidiary of Abbott.⁴²

Post-Transaction Plans

Following the close of the transaction, Exact Sciences will become a wholly owned subsidiary of Abbott.⁴³ The simplified organization chart below shows the post-transaction organizational structure. See the [Exact Sciences Organization Chart](#) for a complete list of Exact Science's subsidiaries.



The entities state that they do not anticipate any changes to Exact Science's governance and management post-transaction.⁴⁴ In the notice, Abbott states, "Exact Sciences will continue to be operated as a standalone business."⁴⁵ Additionally, the entities state that they don't expect the transaction to result in changes to staffing, service offerings, or geographic footprint.⁴⁶

Findings & Potential Impacts

OHA compiled and analyzed data and information to understand and examine the potential impacts of the transaction across various domains including access, cost, quality, and equity in alignment with preliminary review criteria. For more information on OHA’s analysis, see **Appendix A: OHA’s Review**. The below sections summarize OHA’s findings from the preliminary review.

Key Findings

Both entities have a moderate presence in Oregon.

OHA analyzed the entities’ presence in Oregon, including the type and volume of services provided to people in the state.

Exact Sciences’ main business in Oregon is Cologuard tests.

The vast majority of Exact Sciences’ business in Oregon is Cologuard tests. The table below shows service volume for Exact Sciences tests in Oregon.⁴⁷

Service	Count of services (12/1/24 – 11/30/25)
Cologuard	44,502
Prevention Genetics	476
Oncotype	1,689

Cologuard ranked 3rd in Oregon in terms of number of claims for colorectal cancer screenings.

The US Preventive Services Task Force (USPSTF) recommends colorectal cancer screening for all adults aged 45-75.⁴⁸ The estimated number of adults in this age range in Oregon is 1,528,716, or 36% of the total population.⁴⁹

There are multiple types of procedures and tests to screen for colorectal cancer:⁵⁰

- Visualization screening, such as colonoscopy, flexible sigmoidoscopy, and CT colonography, uses a camera to look at the colon and rectum. The recommended screening interval is every 10 years for colonoscopy and every 5 years for flexible sigmoidoscopy and CT colonography.⁵¹
- Stool-based screening includes fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and stool DNA test (Cologuard). USPSTF recommends annual screenings for gFOBT and FIT and screening every 1-3 years for Cologuard.

While gFOBT and FIT detect blood in stool, Cologuard detects biomarkers for cancer in cells from the lining of the colon and rectum.⁵² It is the only stool DNA test approved by the Food and Drug Administration.

OHA used APAC data to assess the volume of Cologuard tests in Oregon, compared to other types of colorectal cancer screening. From 2022 to Q2 2025, Cologuard accounted

for 6% of claims for colorectal cancer screening. Colonoscopy and FOBT accounted for 56% and 37%, respectively.⁵³

Screening type	Percent
Colonoscopy	56%
FOBT Lab Test (gFOBT and FIT)	37%
Cologuard (sDNA FIT Lab Test)	6%
Flexible Sigmoidoscopy	1%
CT Colonography	0.1%

Nationally, Cologuard is the dominant stool-based colorectal cancer screening test

According to the National Cancer Institute’s Cancer Trends Progress Report, in 2023, 11% of adults aged 50-75 were screening for colorectal screening by fecal DNA testing (Cologuard), while 5% were screened by another type of stool-based test.⁵⁴

Test type	Screening Type	Percent of adults aged 50-75 (2023)
Stool-based screening tests	Fecal DNA Test (Cologuard)	11.1%
	Home FOBT	5.1%
Optical or visualization screening tests	Sigmoidoscopy or Colonoscopy	62.8%
	CT Colonography	2.5%

Abbott’s main business in Oregon is workplace pre-employment screening and toxicology.

In Oregon, Abbott’s business comprises two service areas: toxicology labs and Acelis Connected Health, which provides remote patient monitoring services and equipment. The vast majority of Abbott’s Oregon services are related to workplace testing and screening.⁵⁵

Service	Count of services 2023	Count of services 2024	Count of services 2025
Workplace	175,618	153,276	139,386
Government	2,359	2,851	2,277
INR	~1860	~1860	~1860
VAD	~60	~60	~60

The proposed transaction is unlikely to significantly impact access to services in Oregon.

Abbott and Exact Sciences provide different types of services in Oregon.

While both entities provide diagnostic services, the majority of Abbott’s business in Oregon is workplace drug and pre-employment screening, while Exact Sciences focuses on cancer screening.⁵⁶ As such, the transaction will not result in horizontal consolidation in the state.

The proposed transaction is unlikely to result in significant changes to services or market share in Oregon.

The entities state that Exact Sciences will continue to operate as a standalone business and the transaction will not affect the availability of services, stating that there will be no changes to geographic areas served and type and level of services offered.⁵⁷ Abbott and Exact Sciences are not direct competitors for their main business in Oregon and the transaction will not result in horizontal consolidation.⁵⁸

Conclusions

Based on the preliminary review findings, OHA approved the transaction on March 12, 2026. See [Preliminary Review Order](#), dated March 12, 2026. The transaction was approved per ORS 415.501(6)(b) and OAR 409-070-0055(2)(d), because OHA determined that comprehensive review is not warranted given the size and effects of the transaction.

Approval Criteria

The approval criteria are specified in administrative rules for the HCMO program and are consistent with Oregon law. Below is a summary of the main reasons, based on the findings described in this report, why OHA considers the criterion satisfied.

The transaction is not likely to substantially alter the delivery of health care in Oregon.

Following the transaction, no substantial changes are expected to existing services or products available in Oregon. Exact Sciences is expected to continue to operate as a standalone business. Abbott and Exact Sciences are not direct competitors for their operations in Oregon, and the transaction will not result in horizontal consolidation in the state.

Follow-Up Reviews

As required by statute, OHA will conduct follow-up analyses one, two, and five years after the transaction is complete. OHA's monitoring will assess changes following the transaction and whether the entity keeps the commitments included in the notice. As part of the required monitoring activities, OHA may request additional information from the entities. OHA will publish findings and conclusions from follow-up analyses to the HCMO website.

Acronyms & Abbreviations

APAC	Oregon's All Payer All Claims Database
CEO	Chief Executive Officer
COVID	Coronavirus disease 2019
CT	Computed Tomography
DCIS	Ductal Carcinoma In Situ
DME	Durable Medical Equipment
DNA	Deoxyribonucleic Acid
DX	Diagnosis
FIT	Fecal Immunochemical Test
FOBT	Fecal Occult Blood Test
gFOBT	guaiac Fecal Occult Blood Test
HCMO	Health Care Market Oversight
HIV	Human Immunodeficiency Virus
IBC	Invasive Breast Cancer
INR	International Normalized Ratio
OHA	Oregon Health Authority
PT-INR	Prothrombin Time - International Normalized Ratio
sDNA	Stool DNA
USPSTF	United States Preventive Services Task Force
VAD	Vascular Assisted Device

Appendix A: OHA's Review

OHA performed a preliminary review of the proposed transaction to assess its potential impact on Oregon's health care delivery system. OHA's analysis followed the guidelines and methods set out in the HCMO Analytic Framework published January 31, 2022.⁵⁹ The framework is grounded in the goals, standards, and criteria for transaction review and approval outlined in OAR 409-070-0000 through OAR 409-070-0085.

Background Research and Literature Review

OHA conducted background research on the entities involved in the transaction to understand more about the proposed transaction and the entities involved. OHA consulted publicly available sources, including press releases and media reports; Securities & Exchange Commission (SEC) filings; business filings with the Secretary of State in Oregon and other states; entity websites; state agency, professional association, and third party entity reports; reports commissioned by local, state, and federal government; other relevant governmental communications; and peer-reviewed journal articles and research reports.

Analytic Methods

All Payers All Claims Data

The Oregon All Payer All Claims Database (APAC) houses administrative health care data for Oregon's insured populations. It includes medical and pharmacy claims, non-claims payment summaries, member enrollment data, billed premium information and provider information for Oregonians who are insured through certain commercial insurance, Medicaid and Medicare. Information about APAC is available on OHA's website. OHA used APAC claims data to calculate the volume of entity claims in Oregon.

References

¹ Notice Item 16

² Notice Item 13

³ Notice, Item 13.

⁴ HCMO-1 Notice of Material Change Transaction for 073 Abbott-Exact. Item 10f. Available at: <https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/065-HCMO-1-Notice.pdf>.

⁵ Ibid.

⁶ Ibid.

⁷ SEC. Amended and Restated Articles of Incorporation. Available at:

[https://www.sec.gov/Archives/edgar/data/1800/000110465921054917/tm2114110d1_ex3-1.htm#:~:text=Restated%20Article%20R%2DI,dates%20of%20their%20adoption%20are:](https://www.sec.gov/Archives/edgar/data/1800/000110465921054917/tm2114110d1_ex3-1.htm#:~:text=Restated%20Article%20R%2DI,dates%20of%20their%20adoption%20are)

⁸ Abbott. Products and Solutions. Available at: <https://www.abbott.com/en-us/products-solutions>

⁹ HCMO-1 Notice of Material Change Transaction for 073 Abbott-Exact. Item 10. Available at: <https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/065-HCMO-1-Notice.pdf>.

¹⁰ Ibid.

¹¹ Ibid.

¹² Ibid.

¹³ Ibid.

¹⁴ Ibid.

¹⁵ SEC filing

¹⁶ Abbott website

¹⁷ HCMO-1 Notice of Material Change Transaction for 073 Abbott-Exact. Item 10. Available at: <https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/065-HCMO-1-Notice.pdf>.

¹⁸ HCMO-1 Notice of Material Change Transaction for 073 Abbott-Exact. Item 10. Available at: <https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/065-HCMO-1-Notice.pdf>.

¹⁹ Ibid.

²⁰ Ibid. Item 10b

²¹ Ibid.

²² Ibid.

²³ Ibid.

²⁴ Ibid.

²⁵ Ibid.

²⁶ Ibid.

²⁷ Ibid.

²⁸ Ibid.

²⁹ Exact Sciences. Contact. Available at: <https://www.exactsciences.com/about/contact>

³⁰ Notice. Item 11.

³¹ Ibid.

³² Ibid.

³³ Ibid.

³⁴ Ibid.

³⁵ Ibid.

³⁶ Notice 6a.

³⁷ Notice 6a

³⁸ Notice 6c

³⁹ Notice 6c.

⁴⁰ SEC Filing, page 36: <https://www.abbottinvestor.com/static-files/2cec64ee-cb9c-4880-a582-bdb7af1ad810>

⁴¹ SEC Filing page 10, 22: <https://www.abbottinvestor.com/static-files/2cec64ee-cb9c-4880-a582-bdb7af1ad810>

⁴² Notice 6b

⁴³ Notice. 13

⁴⁴ Notice 13

-
- ⁴⁵ Notice. Item 13
- ⁴⁶ Notice 13
- ⁴⁷ Notice 11 f viii
- ⁴⁸ US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
- ⁴⁹ U.S. Census Bureau, American Community Survey 5-Year Estimates: Comparison Profiles 5-Year, 2024, <https://api.census.gov/data/2024/acs/acs5>, accessed on 2026-02-11.
- ⁵⁰ US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
- ⁵¹ US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
- ⁵² US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238
- ⁵³ APAC
- ⁵⁴ Cancer Trends Progress Report. National Cancer Institute, NIH, DHHS, Bethesda, MD, April 2025, <https://progressreport.cancer.gov>, accessed on 2026-02-17.
- ⁵⁵ Notice Item 10
- ⁵⁶ Notice Item 16
- ⁵⁷ Notice Item 13
- ⁵⁸ Notice, Item 13.
- ⁵⁹ Oregon Health Authority, Health Care Market Oversight Analytic Framework, January 31, 2022, available at <https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/OHA-HCMO-Analytic-Framework-FINAL.pdf> (Accessed 8/10/22)